In addition, we have shown that CDDP played a role in the increased activity of HDAC, and the combination of vorinostat and cisplatin produced a 1) synergistic anti-cancer efficacy in NSCLC cell lines in a TRIB1-dependent manner and 2) significant decrease in tumor size and weight in mouse xenograft models [40]. Here, HDAC9 is linked to non-small cell lung carcinoma.